BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Skyepharma PLC (SKYE) Research Update


1/21/2009 10:18:47 AM

LONDON--(Marketwire - January 21, 2009) -


                           Flutiform™ Update


LONDON, UK, 21 January 2009 -- SkyePharma PLC (LSE: SKP) today
announces that it has been notified by its partner Mundipharma that
there may be a few months' delay in the filing of the European
Marketing Authorisation Application for Flutiform™.  This is due to the
need to recruit additional patients into the on-going high dose
strength study, after some patients were assigned to the wrong study
arm in this four-armed study due to a randomisation issue.  There is no
cost implication for the additional work to SkyePharma as a result of
this.


Flutiform™ remains on track for a U.S. New Drug Application filing in
the first quarter of 2009.


For further information please contact:


SkyePharma PLC       Ken Cunningham  +44 20 7491 1777
During office hours  Peter Grant


Financial Dynamics   David Yates     +44 20 7831 3113
Outside office hours Jonathan Birt




About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops
new formulations of existing products to provide a clinical advantage
and life-cycle extension. The Company has twelve approved products in
the areas of oral, inhalation and topical delivery. The Group's
products are marketed throughout the world by leading
pharmaceutical companies. For more information, visit
www.skyepharma.com.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES